Technology | July 31, 2012

FDA Expands Labeling of MultiHance for Magnetic Resonance Angiography

Highest relaxivity contrast agent for CNS imaging now available for MR angiography in adults

 Bracco_Multi Hance Bottles

July 31, 2012 — Bracco Diagnostics Inc., the U.S.-based company of the Bracco Group, announced that the U.S. Food and Drug Administration (FDA) has approved the use of MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

MultiHance was already the highest relaxivity gadolinium-based contrast agent (GBCA) available for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients. The recommended dose for both MRI of the CNS and MRA examinations is 0.1 mmol/kg (0.2 mL/kg) of MultiHance.

The approval of MultiHance in MRA was granted based on data submitted to the FDA that included safety and efficacy results from two large, prospective, multicenter clinical trials (one for each arterial vascular territory: renal and aorto-ilio-femoral). Assessment of diagnostic efficacy for detecting/excluding clinically significant steno-occlusive disease (? 51 percent stenosis) was based on comparisons of sensitivity and specificity between MultiHance MRA and non-contrast MRA, with digital subtraction angiography (DSA) as the standard of truth. Results of both trials showed a statistically significant increase in both sensitivity and specificity of MultiHance-enhanced MRA over non-contrast MRA in detecting clinically significant steno-occlusive disease.

“MultiHance has long been distinguished in the MRI of the CNS as a gadolinium-based contrast agent characterized by a strong increase in relaxivity in any medium containing serum proteins, contributing to increased contrast-to-noise ratio and lesion-to-brain ratio and improved visualization. It also counts a strong record of safety that spans over 14 million administered doses,” said Alberto Spinazzi, senior vice president, group medical and regulatory affairs at Bracco Diagnostics. “The approval of MultiHance for use in MRA of renal and runoff arteries delivers to the radiologist a powerful tool, bringing the power of high relaxivity to the assessment and diagnosis of debilitating vascular diseases.”

For more information: www.bracco.com

Related Content

Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it is critical for overall treatment success and saving patients' lives. Diffusion-weighted magnetic resonance imaging (DWI) may be used to detect a malignancy in various tissues and organs. It has the advantage of providing insight into the diffusion of water molecules in body tissues without exposing patients to radiation.

DWI of the phantom with polyvinylpyrrolidone (PVP) solutions (b value 500 s/mm2). Image courtesy of Kristina Sergunova et al.

News | Magnetic Resonance Imaging (MRI) | June 02, 2020
June 2, 2020 — Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
AIR Recon DL delivers shorter scans and better image quality (Photo: Business Wire)

AIR Recon DL delivers shorter scans and better image quality (Photo: Business Wire).

News | Artificial Intelligence | May 29, 2020
May 29, 2020 — GE Healthcare announced U.S.
United Imaging's uMR OMEGA is designed to provide greater access to magnetic resonance imaging (MRI) with the world’s first ultra-wide 75-cm bore 3T MRI.
News | Magnetic Resonance Imaging (MRI) | May 27, 2020
May 27, 2020 — United Imaging's...
A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue

A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. Image courtesy of Xiandoing Xue, UC Davis

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers at the University of California, Davis offers a...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Advanced imaging data exchange is now live in Colorado due to the partnership of Health Images and the Colorado Regional Health Information Organization

Getty Images

News | Radiology Business | May 18, 2020
May 18, 2020 — 
Experimental Protocol and Representative MRI of Brains at Various Key Points in That Protocol.

Experimental Protocol and Representative MRI of Brains at Various Key Points in That Protocol. (A) Experimental timeline. (B) Representative T2WI (using an 11.7T MRI) of the brain of a postnatal day (PND) 11 pup, 1 day after inducing left HII and prior to hNSC transplantation. Note the beginning of an increasingly intense “water signal” (white) on the left (“HII lesion”). (C) Representative T2WI (using an 11.7T MRI) 3 days post-HII, shortly after implantation of SPIO pre-labeled hNSCs into the contralateral cerebral ventricle (“Lateral Vent”). Note the “HII lesion” on the left becoming hyperintense (white) and the black signal void of the SPIO-labeled hNSCs in the lateral ventricle (black arrow). Red arrows denote the needle track. In contrast to what occurs in the intact brain (Figure S4), in a brain subjected to left HII, the implanted SPIO-labeled hNSCs (black signal void) (black arrow) migrate from the right (“R”) to the left (“L”) hemisphere to enter the lesion. (D and E) Shown here (using a 4.7T MRI) are SPIO-labeled hNSCs (black signal void) (black arrow) at 1 month post-implantation into the contralateral ventricle (D) and, in the same representative animal, at 3 months post-implantation (E)–stably integrated and surrounding a much-reduced residual lesion, with no interval enlargement of the graft or ventricles.

News | Magnetic Resonance Imaging (MRI) | May 13, 2020
May 13, 2020 — Scientists at Sanford Burnham Prebys Medical Discov...
Axial (A) and coronal (B) CT of the abdomen and pelvis with IV contrast in a 57-year-old man with a high clinical suspicion for bowel ischemia. There was generalized small bowel distension and segmental thickening (arrows), with adjacent mesenteric congestion (thin arrow in B), and a small volume of ascites (* in B). Findings are nonspecific but suggestive of early ischemia or infection.

Axial (A) and coronal (B) CT of the abdomen and pelvis with IV contrast in a 57-year-old man with a high clinical suspicion for bowel ischemia. There was generalized small bowel distension and segmental thickening (arrows), with adjacent mesenteric congestion (thin arrow in B), and a small volume of ascites (* in B). Findings are nonspecific but suggestive of early ischemia or infection. Image courtesy of RSNA

News | Coronavirus (COVID-19) | May 11, 2020
May 11, 2020 — Patients with COVID-19 can have b